Drug intelligence / Profile preview

Listeria-PV

Development stage: Preclinical
Lead developer: Loki Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Listeria-PV (AWAKE-LM-PV) is a preclinical-stage cancer immunotherapy developed by Loki Therapeutics using their proprietary AWAKE platform. The therapy utilizes a live attenuated *Listeria monocytogenes* bacterial vector to deliver polio vaccine recall antigens directly into the tumor microenvironment and tumor cells. By presenting these antigens, the drug aims to redirect and activate pre-existing memory T cells—originally generated through childhood polio vaccinations—to recognize and eliminate cancer cells. This approach leverages the potent innate and adaptive immune responses triggered by *Listeria* alongside the high frequency of memory T cells specific to common vaccine antigens, bypassing the need for the immune system to generate a *de novo* response against tumor neoantigens.

Targets

PV3 (Sabin) (Poliovirus type 3 antigen)

Beyond the preview

Go deeper on Listeria-PV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Listeria-PV.

Explore the full profile